This definition appears rarely
See other definitions of CEI
Samples in periodicals archive:
Muiesan G, Alicandri CL, Agabiti-Rosei E, Fariello R, Beschi M, Boni E, Castellano M, Moniti E, Muiesan L, Romanelli G, Zanielli A. Angiotensin-converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension. Am J Cardiol. 1982;49:1420–1424.
Maschio G, Alberti D, Janin G, et al, and the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996; 334: 939–945.
Linear model-based p-values presented in the text. * p<0. 05 versus placebo at same peptide dose, †p<0. 05 versus dipeptidyl peptidase-4 inhibition (DPP4i) at same peptide dose, ‡p<0. 05 versus angiotensin-converting enzyme inhibition (ACEi) at same peptide dose. Bradykinin and Substance P increased tPA release in a dose-dependent manner (see text for p-values).
Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial. Bertrand ME1, Fox KM, Remme WJ, Ferrari R, Simoons ML.
Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol. 2002;40:311-317.